학술논문
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1–positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States
Document Type
Article
Author
Source
In Clinical Genitourinary Cancer February 2021 19(1):e17-e30
Subject
Language
ISSN
1558-7673